Logo

AstraZeneca and MSD's Report Results of Lynparza in P-III PROfound Study for Metastatic Castration-Resistant Prostate Cancer with Homologous Recombination Repair Gene Mutation

Share this

AstraZeneca and MSD's Report Results of Lynparza in P-III PROfound Study for Metastatic Castration-Resistant Prostate Cancer with Homologous Recombination Repair Gene Mutation

Shots:

  • The P-III PROfound study involves assessing of Lynparza (olaparib) vs Enzalutamide/Abiraterone in men with mCRPC and have progressed on prior treatment with anti-cancer therapies with HRRm gene mutation
  • The P-III PROfound study resulted in meeting its 1EPs i.e- improvement in radiographic PFS in men with mCRPC selected for BRCA1/2 or ATM gene mutations- safety & tolerability profiles were consistent with the previous study 
  • Lynparza is a PARP inhibitor act by blocking DNA damage response in tumors harboring HRR mutation including BRCA1/BRCA2. AstraZeneca and MSD are also evaluating Lynparza for prostate cancer and as a 1L therapy in ongoing P-III PROpel study in combination with abiraterone for mCRPC

Click here to­ read full press release/ article

Ref: AstraZeneca | Image: AstraZeneca 


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions